Quest Diagnostics' (DGX) wholly-owned subsidiary Haystack Oncology recently formed a research collaboration with TriSalus Life Sciences. Per the deal, Haystack Oncology, the developer of Haystack MRD, a best-in-class personalized minimal residual disease (MRD) technology, plans to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.This research collaboration holds the pro ...

One of the deadliest diseases in recent times, cancer accounts for approximately 10 million annual deaths worldwide or every one in six people (as revealed by WHO). This hugely increasing incidence of cancer has fueled the demand for oncology across the globe quite enormously. Per a recent report, the $305.1 billion oncology market is currently undergoing a revolutionary change, driven by unprecedented advances in diagnoses and treatments.As cancer research progresses and new technologies emerge, investing ...

The year 2023 has experienced a volatile global economic condition as in the initial months, many sectors rebounded with the opening of lockdowns in several regions. The implementation of bold fiscal stimuli and relief initiatives to spur economic growth positively impacted investment trends globally. However, pressures in the form of inflation, corporate restructuring, difficulties with demand forecasting and geo-political tensions (particularly the Russia-Ukraine, Isael-Hamas and Taiwan-China conflicts) h ...

Quest Diagnostics (DGX) recently announced a collaboration with the leading health and fitness platform, Fitbit, to study the potential of wearable devices to improve metabolic health. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair behavioral and biometric data from Fitbit devices with health insights from Quest Diagnostics' laboratory tests to explore ways to combine and analyze data for the enhanced assessment and management of metabolic health and aid in disease prevention.The latest ...

Blood tests for dozens of types of cancer have been invented. These tests, known as liquid biopsies, could save tens of millions of lives. That’s because there’s currently no good screening procedures for many types of cancers, such as pancreatic cancer and lung cancer. And by the time the tumors cause symptoms, it’s usually too late to save the patients’ lives. Also noteworthy is that these diagnostics, or multi-cancer early detection tests (MCEDs), can save hospitals and health insurers a great deal of mo ...

SECAUCUS, N.J., Jan. 17, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2023 financial results on Thursday, February 1, 2024, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.    The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0 ...

Quest Diagnostics (DGX) recently announced a collaboration with Ultima Genomics, the developer of the revolutionary new ultra-high throughput sequencing architecture. Through the collaboration, the companies aim to improve patient access, affordability and outcomes by expanding the use of highly accurate, cost-efficient and high-volume whole genome sequencing in fast-growth areas, such as solid-tumor minimal residual disease (MRD) testing.The latest development will significantly fortify Quest Diagnostics’ ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find s ...

Quest Diagnostics Inc. (DGX) recently acquired select assets of Steward Health Care System's outreach laboratory services business, which provided services to physicians and patients in Pennsylvania and Ohio. The transaction's financial specifics were kept under wraps.The agreement gives patients and doctors more access to cutting-edge, excellent-quality diagnostic information services.The latest development is likely to broaden Quest Diagnostics' laboratory services offering.More on AgreementQuest Diagnost ...

FREMONT, Calif & SECAUCUS, N.J.--(BUSINESS WIRE)--Ultima Genomics, a developer of a revolutionary new ultra-high throughput sequencing architecture, and Quest Diagnostics (NYSE: DGX), the nation’s leading provider of diagnostic information services, today announced a collaboration involving Ultima’s next generation sequencing (NGS) technology in oncology and other clinical areas. The collaboration aims to improve patient access, affordability and outcomes by broadening the use of highly accurate, cost-ef ...